

M#

Client Ref.:

RECEIVED

MAY 27 2003

037003-0275716

TECH CENTER 1600/2900

**Applicant:** Anderson, et al.

Appln. No.: 09/383,916

**Filing Date:** August 26, 1999

Examiner: Gambel, P.

Group Art Unit: 1644

**Date: May 20, 2003**

Pag 1 of 2

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
PG	AR	4,816,397	03/1989	Boss, et al.	435	68	
I	BR	4,816,567	03/1989	Cabilly, et al.	530	387	
	CR	5,116,964	05/1992	Capon, et al.	536	27	
	DR						

FOREIGN PATENT DOCUMENTS								English Abstract		Translation Readily Available	
			Document Number	Date MM/YYYY	Country	Inventor Name		Enclosed	No	Enclose	No
		ER	0 171 496 B1 /	05/1993	EP	Taniguchi, et al.					
		FR	0 173 494 A2 /	03/1986	EP	Morrison, et al.					
		GR	0 239 400 B1 /	08/1994	EP	Winter, et al.					
		HR	0 194 276 A1 /	03/1986	EP	Neuberger, et al.					
		IR	0 555 880 A2, A3	08/1993	EP	Aruffo, et al.					
		JR	2 177 096 A /	03/1986	GB	Neuberger, et al.					
		KR	WO 92/06193 /	04/1992	WO	Gorman, et al.					
		LR	WO 93/09812 /	05/1993	WO	Lederman, et al.					
		MR	WO 94/28912 /	12/1994	WO	Thompson, et al.					
		NR	WO 95/06481 /	03/1995	WO	Noelle, et al.					
		OR	WO 95/06666	03/1995	WO	Noelle, et al.					

	PR	Armitage, R.J., et al., Molecular and biological characterization of a murine Nature, 357:80—82 (1992)				
	QR	Ben-Nun, A. et al., The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis, Eur J. Immunol. 11, 195-199 (1981)				
	RR	Capon, D.J., et al. Designing CD4 immunoadhesins for AIDS therapy, Nature 337, 525—531 (1989)				
	SR	Dautigny, A., et al., Molecular cloning and nucleotide sequence of a cDNA clone coding for rat brain myelin proteolipid, FEBS Lett. 188(1):33-36 (1985)				
	TR	Durie, F.H., et al., The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease, Research in Immunology, 145(3), 200-205 & 244-249 (1994)				
	UR	Durie, F.H., et al., Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40, Science, 261:1328-1330 (1993)				
	VR	Gerritse, K., et al., CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis, Proc. Natl. Acad. Sci. USA, 93:2499-2504 (1996)				
	WR	Hafler, D.A., et al., The potential of restricted T cell recognition of myelin basis protein epitopes in the therapy of multiple sclerosis, Ann. NY Acad. Sci., 636:251-265 (1991)				

Ришардсман 8/8/03

"etal." "for the" "of the" "form of"



pk	XR	Hollenbaugh, D., et al., The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity, The EMBO J., 11(12):4313-4321 (1992)				
	YR	Karpus, W.J., et al., CD4+ suppressor cells differentially affect the production of IFN-γ by effector cells of experimental autoimmune encephalomyelitis, J. Immunol. 143:3492-3497 (1989)				
	ZR	Laman, J., et al., The role of gp39 (CD40 ligand) in EAE and MS, Journal of Neuroimmunology, 54(1-2):175 (1994)				
	AAR	Lederman, S., et al., Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (Help), J. Exp. Med., 175:1091-1101 (1992)				
	BBR	Lider, O., et al., Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein, J. Immunol. 142:748-752 (1989)				
	CCR	Linsley, P.S., et al., Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation, J. Exp. Med., 178:721-730 (1991)				
	DDR	McCafferty, J., et al., Phage antibodies: filamentous phage displaying antibody variable domains, Nature, 348:552-554 (1990)				
	EER	Miller, A., et al., Antigen-driven bystander suppression after oral administration of antigens, J. Exp. Med. 174:791-798 (1991)				
	FFR	Mokhtarian, F., et al., Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice, Nature 309:356-358 (1984)				
	GGR	Morrison, S., et al., Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains, Proc. Natl. Acad. Sci. U.S.A. 81:6851-6855 (1985)				
	HHR	Noelle, R.J., et al., A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells, Proc. Natl. Acad. Sci. USA 89:6550-6554 (1992)				
	IIR	Olsson, L., et al., Human-human monoclonal antibody-producing hybridomas: technical aspects, Meth. Enzymol., 92:3-17 (1982)				
	JJR	Pesoa, S.A., et al., Regulation of experimental allergic encephalomyelitis. Part 5. Role of the recipient in suppressor cell induction, J. Neuroimmunol 7:131-135 (1984)				
	KKR	Pettinelli, C.B., et al., Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after <i>in vitro</i> activation of lymph node cells by myelin basic protein: requirement for Lyt 1 <sup>+</sup> 2 <sup>+</sup> T lymphocytes, J. Immunol. 127:1420-1423 (1979)				
	LLR	Sobel, R.A., et al., Acute experimental allergic encephalomyelitis in SJL/J mice induced by a synthetic peptide of myelin proteolipid protein, J. Neuropathol. Exp. Neurol. 49(5):468-479 (1990)				
	MMR	Stamenkovic, I., et al., A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas, The EMBO J., 8(5):1403-1410 (1989)				
	NNR	Takeda S., et al., Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences, Nature 314(4):452-454 (1985)				
	OOR	Teng, N. et al., Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production, Proc. Natl. Acad. Sci. U.S.A., 80:7308-7312 (1983)				
	PPR	Tuohy, V.K., et al., Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice, J. Immunol. 142:1523-1527 (1989)				
	QQR	van der Veen, R. et al., The adoptive transfer of chronic relapsing experimental allergic encephalomyelitis with lymph node cells sensitized to myelin proteolipid protein, J. Neuroimmunol. 21:183-191 (1989)				
	RRR	Ward, E.S., et al., Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli, Nature, 341:544-546: (1989)				

Examiner

pkmmgml 8/6/03

Date Considered:

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/383,916
		Filing Date	08/26/99
		First Named Inventor	Anderson et al.
		Art Unit	1644
		Examiner Name	Gambel
Sheet	1	of	1
		Attorney Docket Number	37003-0275716(1995-30-0233D1)

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
PC		US-6,162,432	12/19/00	Wallner et al.	
PC		US-5,885,579	3/23/99	Linsley et al.	
PC		US-5,747,034	05/05/98	de Boer et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

RECEIVED

APR 22 2003

TECH CENTER 1600/2300

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

Examiner Signature	Phump G. Singsil	Date Considered	8/8/03
--------------------	------------------	-----------------	--------

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901:04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Institute for form 1449B/PTO		<b>Complete if Known</b>			
		<b>Application Number</b>	09/383,916		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Filing Date</b>	08/26/99		
		<b>First Named Inventor</b>	Anderson et al.		
		<b>Group Art Unit</b>	1644		
		<b>Examiner Name</b>	Gambel		
<b>Sheet</b>	1	<b>of</b>	1	<b>Attorney Docket Number</b>	37003-0275716(1995-30-0233D1)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
pk		Blazar, B. et al., "Infusion of Anti-B7.1 (CD80) and Anti-B7.2 (CD86) Monoclonal Antibodies Inhibits Murine..." Journal of Immunology 1996 157:3250-3259 ✓	TECH CENTER 1600/2200
		Daikh et al., "The CD28-B6 Costimulatory Pathway and its role in Autoimmune Disease, Journ. of Leukocyte Biology, Vo. 62, August 1997pp. 156-162 ✓	
		Kahan et al., "Immunosuppressive Therapy", Current Opinion in Immunology (1992) 4:553-560 ✓	
		Nickoloff, B. et al., "T Lymphocytes in Skin Lesions of Psoriasis and Mycosis Fungoides..." Blood, Vol. 83, No. 9 (May 1994); pp. 2580-2586 ✓	
		Perrin et al., "Opposing effects of CTLA4-Ig and Anti-CD80 (B7-1) plus Anti-CD86 (B7-2) on ..." Journ. of Neuroimmunology 65(1996) pp. 31-39 ✓	
pk		Yi-qun et al., "Differential Requirements for co-stimulatory signals from B7 family members..." Intl. Immunology, Vol. 8, No. 1, pp. 37-44 ✓	

<b>Examiner Signature</b>	pkw upc n max 8/8/03	<b>Date Considered</b>	
---------------------------	----------------------	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED  
APR 02 2003